Privia Health Group (NASDAQ:PRVA) Price Target Raised to $40.00

Privia Health Group (NASDAQ:PRVA) had its price target lifted by investment analysts at Piper Sandler from $25.00 to $40.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 60.19% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Barclays boosted their target price on shares of Privia Health Group from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. boosted their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, November 29th. Stephens reaffirmed an “overweight” rating and set a $26.00 target price on shares of Privia Health Group in a research report on Thursday, January 2nd. Needham & Company LLC boosted their price target on shares of Privia Health Group from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday. Finally, Macquarie began coverage on shares of Privia Health Group in a report on Monday, December 16th. They issued an “outperform” rating and a $25.00 price target on the stock. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $26.47.

Privia Health Group Trading Down 1.9 %

Shares of PRVA stock opened at $24.97 on Friday. Privia Health Group has a 1 year low of $15.92 and a 1 year high of $26.04. The firm’s fifty day simple moving average is $22.40 and its 200 day simple moving average is $20.60. The firm has a market capitalization of $3.00 billion, a P/E ratio of 249.72, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mackenzie Financial Corp boosted its stake in shares of Privia Health Group by 87.2% in the 4th quarter. Mackenzie Financial Corp now owns 72,391 shares of the company’s stock valued at $1,415,000 after purchasing an additional 33,728 shares in the last quarter. Neo Ivy Capital Management boosted its stake in shares of Privia Health Group by 81.5% in the 4th quarter. Neo Ivy Capital Management now owns 6,540 shares of the company’s stock valued at $127,000 after purchasing an additional 2,936 shares in the last quarter. PharVision Advisers LLC acquired a new position in Privia Health Group during the 4th quarter worth about $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Privia Health Group by 13.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 939,170 shares of the company’s stock worth $18,361,000 after buying an additional 114,647 shares in the last quarter. Finally, Two Sigma Advisers LP acquired a new position in Privia Health Group during the 4th quarter worth about $940,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.